Home > Resources > Whitepapers > Key Drivers of Change in the Global Pharmaceutical Manufacturing Industry

Key Drivers of Change in the Global Pharmaceutical Manufacturing Industry

Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical companies to adopt more costeffective manufacturing strategies resulting in an upsurge in the level of M&A activity in the industry as drugmakers consolidate to reduce costs, diversify product portfolios and expand geographic footprints. This whitepaper provides an overview of the pharmaceutical iopharmaceuticals. PharmaVentures will also share unique insight gained from the divestment of manufacturing operations for some of the world’s leading pharmaceutical companies.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

WakeMed

Level I Trauma Center and tertiary referral hospital, children’s hospital and rehabilitation hospital in Raleigh, N.C. Community hospital in Cary Women’s hospital and family health center in North Raleigh Comprehensive outpatient centers and freestanding emergency departments in Brier Creek, Garner and Apex Freestanding Children's Emergency Department and dedicated Children’s Hospital

OTHER WHITEPAPERS
news image

Market Access Trends in the US, Europe, and Emerging Markets

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

Read More
news image

How to Choose the Right Contract Manufacturing Organisation for Your Pharmaceutical Product

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More
news image

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More
news image

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More
news image

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.

Read More

Market Access Trends in the US, Europe, and Emerging Markets

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

Read More

How to Choose the Right Contract Manufacturing Organisation for Your Pharmaceutical Product

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

Read More

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More

Optimizing the Path from Pre-Clinical to Clinical Development

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

Read More

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing
of highly potent active pharmaceutical ingredients
(HPAPIs) and complex active pharmaceutical
ingredients (APIs) has grown tremendously as demands
in healthcare to bring newer therapies to market quicker
increase.

Read More
More Whitepapers

Spotlight

WakeMed

Level I Trauma Center and tertiary referral hospital, children’s hospital and rehabilitation hospital in Raleigh, N.C. Community hospital in Cary Women’s hospital and family health center in North Raleigh Comprehensive outpatient centers and freestanding emergency departments in Brier Creek, Garner and Apex Freestanding Children's Emergency Department and dedicated Children’s Hospital

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference